Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis

Headache. 2020 Apr;60(4):787-788. doi: 10.1111/head.13779. Epub 2020 Feb 25.

Authors

Raffaele Ornello¹, Ilaria Frattale¹, Francesca Pistoia¹, Simona Sacco^{1

2}, Francesca Notturno²

Affiliations

¹ Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
² Department of Neurology, 'SS. Filippo e Nicola' Hospital, Avezzano (L'Aquila), Italy.

PMID: 32096556
DOI: 10.1111/head.13779

No abstract available

Keywords: erenumab; immunomodulant; migraine; monoclonal antibodies; myasthenia gravis; subcutaneous immunoglobulin.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / pharmacology*
Calcitonin Gene-Related Peptide Receptor Antagonists / administration & dosage
Calcitonin Gene-Related Peptide Receptor Antagonists / pharmacology*
Chronic Disease
Female
Humans
Immunoglobulins / administration & dosage
Immunoglobulins / pharmacology*
Immunologic Factors / administration & dosage
Immunologic Factors / pharmacology*
Injections, Subcutaneous
Migraine without Aura / drug therapy*
Myasthenia Gravis / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
Immunoglobulins
Immunologic Factors
erenumab